Fourth protease inhibitor hits the market. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Fourth protease inhibitor hits the market. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

AIDS Alert. 1997 May;12(5):59-60. Unique Identifier : AIDSLINE AIDS/97702512

Abstract: Nelfinavir (Viracept) became the fourth protease inhibitor to gain marketing clearance from the Food and Drug Administration (FDA). Approved in mid-March, Viracept will make a contribution to the efforts to treat the virus aggressively soon after diagnosis. Viracept was developed by Agouron, and the retail price of treatment will be $15.48 per day. There is a patient assistance program to help those who are financially unable to pay for the treatment.

Keywords: *Drug Approval *Drug Costs Drug Therapy, Combination HIV Infections/*DRUG THERAPY HIV Protease Inhibitors/*THERAPEUTIC USE Human Isoquinolines/*THERAPEUTIC USE Sulfonic Acids/*THERAPEUTIC USE United States United States Food and Drug Administration NEWSLETTER ARTICLE
970830
M9781239

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .